An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This international study is for children aged 3 to 18 who have a brain tumour called medulloblastoma. Doctors are comparing different treatments based on the type of medulloblastoma the child has. They are looking at various chemotherapy drugs, including Doxorubicin, Vincristine, Methotrexate, and Cisplatin, among others. The main goal is to see how many children stay free from the tumour returning (event-free survival). They also want to understand how long children live overall, how the tumour might come back, and how the treatments affect children's hearing, hormone balance, and their overall quality of life. This research aims to find better ways to treat medulloblastoma and help children live healthier lives.
At a glance
What is this study about?
This important international study is looking into ways to treat a type of brain tumour found in children called medulloblastoma. It's designed for children aged 3 to 18 years old. Doctors know that not all medulloblastomas are the same; some are more aggressive, and some respond differently to treatments. This study aims to match the treatment more closely to the specific features of each child's tumour.
The research involves different treatment approaches using various chemotherapy medicines. These medicines are designed to kill cancer cells, and the study will carefully compare which combinations are most effective. The main thing they want to find out is how well children stay free from the tumour coming back after treatment. They will also look at how long children live in total, how their quality of life is affected, and whether there are any long-term side effects like hearing problems or hormone imbalances.
By carefully studying these different treatment plans, the medical community hopes to improve the chances of recovery for children with medulloblastoma, reduce side effects, and ultimately help these children go on to live full and healthy lives. This kind of research is vital for advancing our understanding of this serious illness and finding better ways to care for young patients.
Key takeaways
- This study is for children with medulloblastoma, a brain tumour.
- It aims to find better and safer treatments matched to the specific tumour type.
- The research involves various chemotherapy drugs.
- Doctors will carefully track if the tumour returns and how long children live.
- Quality of life, hearing, and hormone health are also being closely monitored.
- This study helps advance understanding and care for children with medulloblastoma.
Who may be eligible?
This study is looking for children between the ages of 3 and 18 who have been diagnosed with medulloblastoma, a type of brain tumour.
To be considered for the study, your child's medulloblastoma will need to have certain biological features that doctors have identified. This is because the study aims to tailor treatments based on the specific characteristics of the tumour.
It's important to remember that strict rules apply to who can join any clinical study to make sure it's safe and that the results are clear. Your child's doctor will be able to tell you if your child meets all the specific requirements.
- Is your child between 3 and 18 years old?
- Has your child been diagnosed with medulloblastoma?
- Has your child's doctor confirmed their medulloblastoma has specific biological features relevant to this study?
- Is your family able to commit to regular hospital visits and follow-up appointments?
- Are you comfortable with the possibility of new or combined chemotherapy treatments?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If your child takes part in this study, they will receive a specific treatment plan that involves various chemotherapy drugs. This treatment will be carefully monitored by their medical team. The study will likely involve regular hospital visits for treatments, check-ups, and tests like blood tests, scans, and hearing tests to see how they are responding to treatment and to check for any side effects.
Doctors will closely watch measures like overall survival, how long your child stays free from the disease, and how the treatment affects their daily life, including their physical and emotional well-being, learning, and social development. They will also pay special attention to specific side effects such as hearing problems (audiological toxicity) and how hormones are working (endocrine function). The total length of your child's participation will depend on the specific treatment plan and follow-up schedule, which can last for several years.
Potential risks and benefits
Locations (10)
- —Spain
- —Netherlands
- —Czechia
- —Sweden
- —Belgium
- —Finland
- —France
- —Germany
- —Austria
- —Italy
Common questions
What is medulloblastoma?
Medulloblastoma is a type of cancerous brain tumour that starts in the part of the brain called the cerebellum, which helps with balance and movement.
Why are different treatments being studied?
Doctors are studying different treatments because not all medulloblastomas are the same. They want to find the best and safest treatment for each specific type of tumour.
What do 'event-free survival' and 'overall survival' mean?
Event-free survival means how long a child lives without the cancer coming back or getting worse. Overall survival means how long a child lives after being diagnosed.
Will my child's quality of life be considered?
Yes, absolutely. The study will look closely at how the treatments affect your child's quality of life, including their health, hearing, energy levels, and daily activities, using special questionnaires for children and parents.
Can my child leave the study at any time?
Yes, you can choose to withdraw your child from the study at any point, and it will not affect their ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.